Rubicon Organics to Commence Trading on the TSX Venture Exchange
Trading on TSX Venture Exchange to commence September 22, 2020 under ticker symbol ROMJVANCOUVER, British Columbia, Sept. 18, 2020 (GLOBE […]
Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the ESMO Virtual Congress 2020
– AUTO3 shows promise of a highly differentiated product profileConference call and webcast to be held Friday, September 18, 2020 at […]
Victory Square Technologies Portfolio Company V2 Games Acquires Techstars 2019 Alumni Company “GameOn”
GameOn makes it easier, faster and safer to get in the game through free play prediction games for the everyday […]
Agenus Presents Results from Two Large Cervical Cancer Trials at ESMO
160 patient balstilimab (PD-1) monotherapy trial achieves response rates of 14% in all treated patients and 19% in PD-L1 positive […]
First Production-Scale Batch of Beyond Tobacco™ Material Completed, Shipped to Manufacturer to Make Commercial Samples
LAS VEGAS and VANCOUVER, British Columbia, Sept. 18, 2020 (GLOBE NEWSWIRE) — TAAT LIFESTYLE & WELLNESS LTD. (CSE: TAAT) (OTC: […]
COMPASS Pathways announces pricing of upsized initial public offering
COMPASS Pathways announces pricing of upsized initial public offeringLondon, UK – September 18, 2020COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a […]
OneWater Marine Inc. Prices Public Offering of Common Stock
BUFORD, Georgia, Sept. 17, 2020 (GLOBE NEWSWIRE) — OneWater Marine Inc. (NASDAQ: ONEW) (“OneWater” or the “Company”) announced today the […]
Immutep Announces Improving Results from Stage I of Phase II TACTI-002 Study
Three complete responses (complete disappearance of all lesions) reported: two in 2nd line head and neck squamous cell carcinoma (HNSCC) […]
Athira Pharma Announces Pricing of Initial Public Offering
SEATTLE, Sept. 17, 2020 (GLOBE NEWSWIRE) — Athira Pharma, Inc., (Nasdaq: ATHA) (“Athira”), a late clinical-stage biopharmaceutical company focused on […]
Immutep Reports Improving Results from INSIGHT-004 Trial
41.7% of patients showed a Partial Response to the combination therapy of eftilagimod alpha and avelumab (previously 33%)Encouraging early anti-tumour […]
